Business news – Page 42
-
OpinionBeyond buckets and batches
Embracing flow chemistry means leaving behind some faithful friends
-
-
NewsSocieties launch science primers for UK judges
Short documents will help judges make sense of scientific evidence
-
BusinessTargeting rare diseases
Is working on genetic mutations that affect only a few in every thousand people risky?
-
BusinessBayer forms cancer-drug partnership with Loxo
Alliance could see Loxo net up to $1.55bn in upfront and milestone payments
-
NewsRepublican tax bill backed by industry but not science
Chemical industry says tax overhaul will be fairer, but science groups warn that it will harm research
-
FeatureStaying one step ahead of the game
Clare Sansom examines the need for agile drug development when tackling emerging viral disease outbreaks
-
BusinessChina clamps down on polluting factories
Thousands of factories face closure or sanctions as authorities exercise new powers to curb air and water pollution
-
BusinessChina moves in on US shale gas
Alaska and West Virginia have welcomed investment from Chinese entities to develop US shale resources
-
BusinessIndia's science start-ups
A growing community of entrepreneurs are overcoming cultural and infrastructure barriers to commercialise their research
-
BusinessChuck Norris versus gadolinium
US action star is suing 11 drug firms for $10m, claiming his wife was poisoned by gadolinium from her MRIs
-
OpinionThe value of quantification
A skills gap is emerging in organic synthesis that needs to be closed
-
BusinessValeant relinquishes female libido drug
Struggling firm is returning Sprout Pharmaceuticals subsidiary to original shareholders to resolve dispute over marketing
-
BusinessGenerics firms Amneal and Impax to merge
Deal continues consolidation trend, based on portfolio expansion and simplifying supply chains
-
BusinessNovartis to buy AAA for radioligand cancer drugs
$3.9bn deal follows European approval of Advanced Accelerator Applications’ first-in-class radionuclide drug Lutathera
-
BusinessExxonMobil agrees to install pollution controls
Settlement with US government compels firm to improve emissions control and monitoring at eight chemical plants
-
BusinessLilly and CureVac to collaborate on mRNA cancer vaccines
Deal could see CureVac net up to $1.8 billion in upfront and milestone payments
-
BusinessInvestor kills planned Huntsman–Clariant merger
Merger of equals abandoned after major Clariant investor said the deal would destroy stakeholder value
-
NewsGlyphosate exposure jumped substantially in two decades in Californian community
Rising levels of herbicide linked to US introduction of GM crops in 1994
-
BusinessGSK’s shingles vaccine gets thumbs up in North America
Inoculation slated to be a blockbuster